A systematic review [45] revealed that the majority of the cataloged predicted pathogenic PALB2 variants, specifically 911 cases (92.5%), were documented in breast cancer patients, while 49 cases (5.0%) were observed in patients with ovarian tumors, and 24 cases (2.4%) were recorded in patients with pancreatic cancer. Here, PALB2 is linked to breast carcinoma.